1.

Record Nr.

UNINA9910841332803321

Autore

LaMattina John L

Titolo

Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina

Pubbl/distr/stampa

Hoboken, N.J., : John Wiley & Sons, c2009

ISBN

1-118-15896-2

1-281-93930-7

9786611939304

0-470-43467-8

0-470-43465-1

Descrizione fisica

1 online resource (156 p.)

Disciplina

338.4761519

615/.19

Soggetti

Drug development - United States

Pharmaceutical industry - United States

Drugs - Research - United States

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references (p. 124-132) and index.

Nota di contenuto

Cholesterol drugs are unnecessary -- Industry is more interested in 'me-too' drugs than in innovation -- It takes industry too long to discover new drugs -- Drugs are discovered by academia -- New medicines add costs but little benefit -- Big pharma has failed and should learn from biotech success -- The industry invents diseases -- New drugs are less safe than traditional medicines -- Industry spends more on advertising than R&D -- Industry does not care about diseases of the developing world -- Big pharma's day has passed -- Final reflections.

Sommario/riassunto

This book answers the questions about the process and costs of pharmaceutical R & D in a compelling narrative focused on the discovery and development of important new medicines. It gives an insider's account of the pharmaceutical industry drug discovery process, the very real costs of misperceptions about the industry, the high stakes--both economic and scientific--of developing drugs, the triumphs that come when new compounds reach the market and save



lives, and the despair that follows when new compounds fail. In the book, John LaMattina, former president of Pfizer Global Research and Devel